PDCD1 and hepatocellular carcinoma: Based on these findings, theoretically, combination treatment with hepatic arterial infusion chemotherapy, lenvatinib, and PD-1 inhibitors could achieve more pronounced therapeutic effects in patients with unresectable HCC.